Welcome to STN International! Enter x:x

LOGINID: SSSPTA1600LXD

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

```
* * * * * * * * *
                     Welcome to STN International
NEWS 1
                 Web Page URLs for STN Seminar Schedule - N. America
                 "Ask CAS" for self-help around the clock
NEWS 2
NEWS 3
         SEP 09
                 CA/CAplus records now contain indexing from 1907 to the
                 present
         DEC 08
NEWS
                 INPADOC: Legal Status data reloaded
NEWS
      5
         SEP 29
                 DISSABS now available on STN
                 PCTFULL: Two new display fields added
NEWS
      6
         OCT 10
         OCT 21
NEWS
                 BIOSIS file reloaded and enhanced
                 BIOSIS file segment of TOXCENTER reloaded and enhanced
NEWS 8
        OCT 28
NEWS 9 NOV 24
                 MSDS-CCOHS file reloaded
NEWS 10 DEC 08
                 CABA reloaded with left truncation
NEWS 11
         DEC 08
                 IMS file names changed
         DEC 09
NEWS 12
                 Experimental property data collected by CAS now available
                 in REGISTRY
NEWS 13
         DEC 09
                 STN Entry Date available for display in REGISTRY and CA/CAplus
NEWS 14
         DEC 17
                 DGENE: Two new display fields added
         DEC 18
                 BIOTECHNO no longer updated
NEWS 15
NEWS 16 DEC 19
                 CROPU no longer updated; subscriber discount no longer
                 available
NEWS 17
         DEC 22
                 Additional INPI reactions and pre-1907 documents added to CAS
                 databases
         DEC 22
                 IFIPAT/IFIUDB/IFICDB reloaded with new data and search fields
NEWS 18
NEWS 19
         DEC 22 ABI-INFORM now available on STN
NEWS EXPRESS DECEMBER 28 CURRENT WINDOWS VERSION IS V7.00, CURRENT
              MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
              AND CURRENT DISCOVER FILE IS DATED 23 SEPTEMBER 2003
NEWS HOURS
              STN Operating Hours Plus Help Desk Availability
NEWS INTER
              General Internet Information
NEWS LOGIN
              Welcome Banner and News Items
NEWS PHONE
              Direct Dial and Telecommunication Network Access to STN
              CAS World Wide Web Site (general information)
NEWS WWW
```

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 16:28:06 ON 05 JAN 2004

=> file reg COST IN U.S. DOLLARS

FULL ESTIMATED COST

SINCE FILE TOTAL ENTRY SESSION 0.21 0.21

FILE 'REGISTRY' ENTERED AT 16:28:24 ON 05 JAN 2004 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 4 JAN 2004 HIGHEST RN 634148-43-9 DICTIONARY FILE UPDATES: 4 JAN 2004 HIGHEST RN 634148-43-9

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2003

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at: http://www.cas.org/ONLINE/DBSS/registryss.html

=> s tetrahydrolipstatin L1 1 TETRAHYDROLIPSTATIN

=> d L1

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2004 ACS on STN

RN 96829-58-2 REGISTRY

CN L-Leucine, N-formyl-, (1S)-1-[[(2S,3S)-3-hexyl-4-oxo-2-oxetanyl]methyl]dodecyl ester (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN L-Leucine, N-formyl-, 1-[(3-hexyl-4-oxo-2-oxetanyl)methyl]dodecyl ester, $[2S-[2.alpha.(R^*),3.beta.]]$ -

OTHER NAMES:

CN (-)-Tetrahydrolipstatin

CN Orlistat

CN Ro 18-0647/002

CN Tetrahydrolipstatin

CN Xenical

FS STEREOSEARCH

DR 111397-16-1

MF C29 H53 N O5

LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*,
BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB,
CEN, CHEMCATS, CHEMINFORMRX, CIN, CSCHEM, DDFU, DIOGENES, DRUGU, EMBASE,
IMSCOSEARCH, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, MRCK*,
PHAR, PROMT, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL

(*File contains numerically searchable property data)

Other Sources: WHO

Absolute stereochemistry.

Me
$$(CH_2)$$
 $\frac{1}{5}$ $\frac{H}{S}$ $\frac{H}{S}$ $\frac{Bu-i}{S}$ $\frac{H}{S}$ $\frac{Bu-i}{S}$ $\frac{Me}{S}$

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

321 REFERENCES IN FILE CA (1907 TO DATE)

2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

321 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file caplus COST IN U.S. DOLLARS

SINCE FILE TOTAL ENTRY SESSION

8.51

8.30

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 16:31:34 ON 05 JAN 2004 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 5 Jan 2004 VOL 140 ISS 2 FILE LAST UPDATED: 4 Jan 2004 (20040104/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s hipe foam

74 HIPE

22 HIPES

81 HIPE

(HIPE OR HIPES)

90153 FOAM

50588 FOAMS

99590 FOAM

(FOAM OR FOAMS)

L2 12 HIPE FOAM

(HIPE(W) FOAM)

=> s L1 and L2

321 L1

L3 0 L1 AND L2

=> s L2 and Tg 56422 TG 2905 TGS 58708 TG

(TG OR TGS)

2 L2 AND TG

=> d L4 1-2 ibib abs hitrn

ANSWER 1 OF 2 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:1004369 CAPLUS

DOCUMENT NUMBER: 140:5841

TITLE: Polymeric foam materials derived from high internal

phase emulsions for clothing insulation

INVENTOR(S): Dyer, John Collins; Desmarais, Thomas Allen; Hird,

Bryn

PATENT ASSIGNEE(S): The Procter & Gamble Company, USA

SOURCE: U.S. Pat. Appl. Publ., 12 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

KIND DATE PATENT NO. APPLICATION NO. DATE -----------US 2001-992628 20011106 US 2002123283 A1 20020905 US 2000-246377P P 20001107 PRIORITY APPLN. INFO.:

The present invention relates to polymeric foam materials useful as insulation in clothing articles. These polymeric foams are prepd. by polymn. of certain water-in-oil emulsions having a relatively high ratio of water phase to oil phase, commonly known in the art as "HIPEs.". As used herein, polymeric foam materials which result from the polymn. of such emulsions are referred to hereafter as "HIPE foams

.". These HIPE foams comprise a generally hydrophobic, flexible or semi-flexible, nonionic polymeric foam structure of interconnected open-cells. The HIPE foams of the present invention have a sp. surface area per foam vol. of at least about 0.01~m 2 /cc, a d. of less than about 0.0625~g/cc and a glass transition temp. (Tg) between about -40.degree. C. and about 90.degree. C. A divinylbenzene-1,6-hexanediol diacrylate-isoprene-styrene copolymer foam was prepd. using calcium chloride as an electrolyte and potassium persulfate as the water sol. initiator.

ANSWER 2 OF 2 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2000:608817 CAPLUS

DOCUMENT NUMBER: 133:208960

TITLE: Continuous curing of high internal phase emulsions

(HIPE) into HIPE foams

INVENTOR(S): Desmarais, Thomas Allen; Shiveley, Thomas Michael;

Dyer, John Collins; Hird, Bryn; Dick, Stephen Thomas

PATENT ASSIGNEE(S): Procter & Gamble Co., USA SOURCE: PCT Int. Appl., 38 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE _____ ----_____ -----

```
W: AE, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR,
          W: AE, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
      EP 1169374
                         A1 20020109 EP 2000-910258 20000218
          R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
               IE, SI, LT, LV, FI, RO
      US 6525106
                     B1 20030225
                                                 US 2001-890918
                                                                      20010807
PRIORITY APPLN. INFO.:
                                              US 1999-121152P P 19990222
                                               WO 2000-US4353 W 20000218
      Flexible, microporous, open-celled polymeric foam materials are obtained
AB
      in a continuous curing process comprising (1) continuously providing a
      HIPE, (2) transferring the HIPE into a curing chamber which provides the
      means to maintain the HIPE at curing temp., (3) maintaining the HIPE in
      the curing chamber for sufficient period of time for at least partial
      curing of the HIPE into a nascent HIPE foam, (4)
      continuously withdrawing the nascent foam from the chamber, and (5)
      further processing the nascent foam into cured HIPE foam
      . The HIPE comprises (A) an oil phase including 1-20 wt.% of an
      emulsifier suitable for forming a water-in-oil emulsion and 85-99 wt.% of
      a water-insol. monomer component consisting of 5-80 wt.% of a
      monofunctional monomer capable of forming a polymer having a Tq
      .ltoreq.35.degree., 0-70 wt.% of other monofunctional monomers, and 5-80
      wt.% of a polyfunctional crosslinking agent and (B) a water phase
      comprising an aq. soln. contg. 0.2-40 wt.% of a water-sol. electrolyte and
      a polymn. initiator, where the vol. to wt. ratio of the water phase to the
      oil phase is 8:1 to 140:1.
REFERENCE COUNT:
                             3
                                    THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
                                    RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT
=> d L2 1-12 ibib abs hitrn
     ANSWER 1 OF 12 CAPLUS COPYRIGHT 2004 ACS on STN
                            2003:1004369 CAPLUS
ACCESSION NUMBER:
DOCUMENT NUMBER:
                             140:5841
                             Polymeric foam materials derived from high internal
TITLE:
                             phase emulsions for clothing insulation
                             Dyer, John Collins; Desmarais, Thomas Allen; Hird,
INVENTOR(S):
                             Bryn
                             The Procter & Gamble Company, USA
PATENT ASSIGNEE(S):
                             U.S. Pat. Appl. Publ., 12 pp.
SOURCE:
                             CODEN: USXXCO
DOCUMENT TYPE:
                             Patent
                             English
LANGUAGE:
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:
     PATENT NO. KIND DATE
                                                 APPLICATION NO. DATE
      _____ ____
                                                 _____
     US 2002123283
                        A1 20020905
                                               US 2001-992628 20011106
PRIORITY APPLN. INFO.:
                                             US 2000-246377P P 20001107
     The present invention relates to polymeric foam materials useful as
     insulation in clothing articles. These polymeric foams are prepd. by
```

polymn. of certain water-in-oil emulsions having a relatively high ratio of water phase to oil phase, commonly known in the art as "HIPEs.". As

A1

20000831

WO 2000-US4353

WO 2000050498

used herein, polymeric foam materials which result from the polymn. of such emulsions are referred to hereafter as "HIPE foams

.". These HIPE foams comprise a generally

hydrophobic, flexible or semi-flexible, nonionic polymeric foam structure of interconnected open-cells. The HIPE foams of the present invention have a sp. surface area per foam vol. of at least about 0.01 m 2 /cc, a d. of less than about $0.06\overline{25}$ g/cc and a glass transition temp. (Tg) between about -40.degree. C. and about 90.degree. C. A divinylbenzene-1,6-hexanediol diacrylate-isoprene-styrene copolymer foam was prepd. using calcium chloride as an electrolyte and potassium persulfate as the water sol. initiator.

ANSWER 2 OF 12 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER:

2003:325436 CAPLUS

DOCUMENT NUMBER:

138:310463

TITLE:

Low-density materials for use in inertial fusion

targets

AUTHOR(S):

Steckle, Warren P., Jr.; Nobile, Arthur, Jr.

CORPORATE SOURCE:

Materials Science and Technology Division Polymer and Coatings Group, Los Alamos National Laboratory, Los

Alamos, NM, 87545, USA

SOURCE:

LANGUAGE:

Fusion Science and Technology (2003), 43(3), 301-306

CODEN: FSTUCY

PUBLISHER: DOCUMENT TYPE: American Nuclear Society Journal; General Review

English

A review. Low-d. polymer foams have been an integral part of targets used AB in inertial confinement fusion (ICF) expts. Target designs are unique in the ICF program and targets are made on an individual basis. Costs for these targets are high due to the time required to machine, assemble and characterize each target. To produce targets in high vol. and at low cost, a polymer system is required that is amenable to scale up. High internal phase emulsion (HIPE) polystyrene is a robust system that offers great flexibility in terms of tailoring the d. and incorporating metal dopants. Emulsions used to fabricate HIPE foams

currently are made in a batch process. With the use of metering pumps for both the water and oil phases, emulsions can be produced in a continuous process. This not only makes these foams potential candidates for direct-drive capsules, but high-Z dopants can be metered in making these foams attractive for hohlraum components in indirect-drive systems.

Prepn. of HIPE foams are discussed for both direct-drive and indirect-drive systems.

REFERENCE COUNT:

THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS 11 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ANSWER 3 OF 12 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER:

2001:338620 CAPLUS

DOCUMENT NUMBER:

134:354205

TITLE:

Foam materials obtained from high internal phase

emulsions

INVENTOR(S):

Dyer, John Collins; Hortel, Thomas Charles; Mcchain, Robert Joseph; Desmarais, Thomas Allen; Young, Gerald

Alfred

PATENT ASSIGNEE(S):

The Procter + Gamble Company, USA

SOURCE:

PCT Int. Appl., 36 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

TANGUAGE:

English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO. KIND DATE

APPLICATION NO. DATE

```
WO 2000-US30105 20001101
                             20010510
     WO 2001032761
                      A1
         W: AE, AG, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH,
             CN, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EE, EE, ES, FI, FI,
             GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR,
             KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX,
             MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD,
             RU, TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
                                            US 2000-698343 20001027
                             20020423
                        В1
     US 6376565
                             20020925
                                            EP 2000-976791
                                                              20001101
     EP 1242519
                        Α1
             AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
                                                              20001101
                                             JP 2001-535455
     JP 2003514052
                        T2 20030415
                                          US 1999-163064P P 19991102
PRIORITY APPLN. INFO.:
                                         WO 2000-US30105 W 20001101
     Described are implements made from a durable high internal phase emulsion
AΒ
     (HIPE) foam material which comprises a HIPE
     foam having: A. a dry d. of less than about 100 mg/cc; B. a glass
     temp. of -40 to +90.degree.; and C. a toughness index of at least about
     75, wherein foam comprises a vinyl polymer and the foam has a substantially
     two-dimensional structure or substantially a tridimensional structure..
     The Toughness Index relates properties related to durability (e.g., d.,
     tan[.delta.] height, glass transition temp., and abrasion resistance) into
     a single composite descriptor thereof. Exemplary implements include:
     wipes, toys, stamps, art media, targets, food prepn. implements, plant
     care implements, and medical wraps.
                                THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
                          2
REFERENCE COUNT:
                                RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT
     ANSWER 4 OF 12 CAPLUS COPYRIGHT 2004 ACS on STN
                          2001:338395 CAPLUS
ACCESSION NUMBER:
                          134:344638
DOCUMENT NUMBER:
                          Method of making shaped foam with high internal phase
TITLE:
                          emulsions
                          Noel, John Richard; Dyer, John Collins; Desmarais,
INVENTOR(S):
                          Thomas Allen; Lipic, Paul Martin; Hammons, John Lee
                          The Procter + Gamble Company, USA
PATENT ASSIGNEE(S):
                          PCT Int. Appl., 60 pp.
SOURCE:
                          CODEN: PIXXD2
                          Patent
DOCUMENT TYPE:
                          English
LANGUAGE:
FAMILY ACC. NUM. COUNT:
PATENT INFORMATION:
                                             APPLICATION NO. DATE
     PATENT NO.
                       KIND DATE
                                             _____
                                            WO 2000-US30106 20001101
                             20010510
     WO 2001032227
                      A1
         MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM,
             TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD,
             RU, TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
              DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
              BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
```

B1 20020618

US 6406648

US 2000-698921 20001027

EP 2000-976792 20001101 A1 20021002 EP 1244475 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR T2 20030408 JP 2001-534431 JP 2003512942

PRIORITY APPLN. INFO.:

US 1999-163213P P 19991102 WO 2000-US30106 W 20001101

Described is a method of forming and curing high internal phase emulsions AΒ (HIPEs) into shaped three dimensional foam implements. In general the method uses the steps of: providing a HIPE, depositing the HIPE into a mold cavity having a predetd. three dimensional shape, curing the HIPE in the mold cavity to form a HIPE foam, and stripping the HIPE foam from the mold cavity to form the three dimensional foam implement. The molded implements are widely useful as components in absorbent articles, toys, insulation, and other uses where a combination of low-d. and tridimensional shape are desired. A molded tridimensional HIPE foam suitable for use as an absorbent core was prepd. from a water phase contg. potassium persulfate 0.05, calcium chloride 10, and water q.s. to 100 %, and an oil phase contg. 2-ethylhexyl acrylate 59.4, styrene 30, divinyl benzene 15.6, and diglycerol monooleate 8 %.

REFERENCE COUNT:

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ANSWER 5 OF 12 CAPLUS COPYRIGHT 2004 ACS on STN

3

2001:286118 CAPLUS ACCESSION NUMBER:

135:63009 DOCUMENT NUMBER:

TITLE:

High-performance poly(butylene oxide)/poly(ethylene oxide) block copolymer surfactants for the preparation

of water-in-oil high internal phase emulsions

AUTHOR(S):

SOURCE:

Mork, Steven W.; Rose, Gene D.; Green, D. Patrick The Dow Chemical Company, Midland, MI, 48674, USA Journal of Surfactants and Detergents (2001), 4(2),

127-134

CODEN: JSDEFL; ISSN: 1097-3958

PUBLISHER:

CORPORATE SOURCE:

AOCS Press DOCUMENT TYPE: Journal English LANGUAGE:

High-performance surfactants have been developed for the prepn. of water-in-oil high internal phase emulsions (HIPE), particularly for the prepn. of polymd. HIPE foams. High-efficiency surfactants with poly(butylene oxide)/poly(ethylene oxide) (BO/EO) block copolymer backbones have been developed that can stabilize an HIPE through polymn. at concns. as low as 0.006 wt% based on total emulsion wt. Polymerizable versions have been developed that bind into the polymeric foam backbone. BO/EO block copolymer surfactants also allow prepn. of polymd. HIPE foams without salt in the aq. phase. HIPE with the BO/EO surfactants have been prepd. at room temp. and polymd. at temps. exceeding 90.degree.C. By minimizing the required amt. of surfactant, allowing the surfactant to react during HIPE polymns., eliminating the need for salt, and stabilizing over a broad range of temps., BO/EO block copolymer surfactants have demonstrated their place as high-performance HIPE surfactants.

REFERENCE COUNT:

THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ANSWER 6 OF 12 CAPLUS COPYRIGHT 2004 ACS on STN

39

2000:608817 CAPLUS ACCESSION NUMBER:

DOCUMENT NUMBER:

133:208960

TITLE:

Continuous curing of high internal phase emulsions

(HIPE) into HIPE foams

INVENTOR(S):

Desmarais, Thomas Allen; Shiveley, Thomas Michael; Dyer, John Collins; Hird, Bryn; Dick, Stephen Thomas PATENT ASSIGNEE(S):

Procter & Gamble Co., USA

SOURCE:

PCT Int. Appl., 38 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent English

LANGUAGE:

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

```
APPLICATION NO. DATE
     PATENT NO.
                       KIND DATE
                                                 _____
                        A1 20000831 WO 2000-US4353 20000218
     WO 2000050498
         W: AE, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT,
               RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR, TT, TZ, UA, UG,
               US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
          RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
               DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
               CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
                         A1 20020109 EP 2000-910258 20000218
     EP 1169374
          R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
               IE, SI, LT, LV, FI, RO
                                                  US 2001-890918
                                                                    20010807
                        B1 20030225
     US 6525106
                                              US 1999-121152P P 19990222
PRIORITY APPLN. INFO .:
                                              WO 2000-US4353 W 20000218
```

Flexible, microporous, open-celled polymeric foam materials are obtained AΒ in a continuous curing process comprising (1) continuously providing a HIPE, (2) transferring the HIPE into a curing chamber which provides the means to maintain the HIPE at curing temp., (3) maintaining the HIPE in the curing chamber for sufficient period of time for at least partial curing of the HIPE into a nascent HIPE foam, (4) continuously withdrawing the nascent foam from the chamber, and (5) further processing the nascent foam into cured HIPE foam The HIPE comprises (A) an oil phase including 1-20 wt.% of an emulsifier suitable for forming a water-in-oil emulsion and 85-99 wt.% of a water-insol. monomer component consisting of 5-80 wt.% of a monofunctional monomer capable of forming a polymer having a Tg .ltoreq.35.degree., 0-70 wt.% of other monofunctional monomers, and 5-80 wt.% of a polyfunctional crosslinking agent and (B) a water phase comprising an aq. soln. contg. 0.2-40 wt.% of a water-sol. electrolyte and a polymn. initiator, where the vol. to wt. ratio of the water phase to the oil phase is 8:1 to 140:1.

REFERENCE COUNT:

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ANSWER 7 OF 12 CAPLUS COPYRIGHT 2004 ACS on STN

3

ACCESSION NUMBER:

1999:543854 CAPLUS

TITLE:

Polymeric surfactants for the preparation of high

internal phase emulsion (HIPE) foams

AUTHOR(S): CORPORATE SOURCE: Mork, Steven W.; Green, D. Patrick; Rose, Gene D. Corporate R&D, The Dow Chemical Company, Midland, MI,

48674, USA

SOURCE:

Book of Abstracts, 218th ACS National Meeting, New Orleans, Aug. 22-26 (1999), PMSE-284. American

Chemical Society: Washington, D. C.

CODEN: 67ZJA5

DOCUMENT TYPE:

Conference; Meeting Abstract

LANGUAGE:

English

High internal phase emulsions (HIPEs) are emulsions with greater than about 70% internal phase and can be prepd. with internal phases in excess of 99%. Very low d. polymeric foams can be prepd. with exceptional control of cell and pore structure by polymg. the continuous phase and removing the internal phase of a HIPE. High demands are placed on HIPE surfactant systems due to the fact dispersed phase droplets are actually compressed against one another into a non-spherical geometric packing. Polyoxyethylene/polyoxybutylene block copolymer surfactants have been developed which are esp. efficient at stabilizing HIPE systems. As little as 0.125 wt.-percent surfactant, based on the continuous phase, has been successfully used in prepg. HIPE foams. Addnl., polymerizable surfactants have been developed which provide the choice of a variety of functionalities that can be bound in-situ on and near the surface of the foam walls.

ANSWER 8 OF 12 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER:

1999:513352 CAPLUS

DOCUMENT NUMBER:

132:152870

TITLE:

Polymeric surfactants for the preparation of high

internal phase emulsion (HIPE) foams

AUTHOR(S):

Mork, Steven W.; Green, D. Patrick; Rose, Gene D. The Dow Chemical Company, Midland, MI, 48674, USA

CORPORATE SOURCE: SOURCE:

Polymeric Materials Science and Engineering (1999),

81, 515-517

CODEN: PMSEDG; ISSN: 0743-0515

American Chemical Society

PUBLISHER: DOCUMENT TYPE:

Journal

LANGUAGE:

English

Nonionic and anionic surfactants are developed which are esp. efficient at AΒ stabilizing HIPEs through their polymn., allowing very little surfactant to be used in HIPE foam prepn. Highly efficient

polymeric surfactants allow open cell structures to be prepd. with .gtoreq. 0.125 wt.% surfactant based on continuous phase. These surfactants allow HIPE foams to be prepd. with reduced

extractable surfactant and with bound functionality in the foam structure. THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS REFERENCE COUNT: 1.3 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ANSWER 9 OF 12 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER:

1998:816114 CAPLUS

DOCUMENT NUMBER:

130:71602

TITLE:

Process for making foams useful as absorbent members

for catamenial pads

INVENTOR(S):

Dyer, John Collins

PATENT ASSIGNEE(S):

The Procter & Gamble Company, USA

SOURCE:

U.S., 24 pp., Cont.-in-part of U.S. Ser. No. 370,697,

abandoned. CODEN: USXXAM

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.	KIND	DATE		AI	PLI	CATIO	ои ис	o. 	DATE			
ES, FI,	GB, GE	19981215 19960730 20001031 19960718 19960718 , AZ, BB, , HU, IS, , MK, MN,	BG, JP,	ZA EC CA WC BR, KE,	A 19 G 19 A 19 D 19 BY, KG,	ΚP,	34 4 2086 S388 CH, KR,	42 CN, KZ,	LK,	0109 0110 0111 0111 DE, LR,	LS,	LT,

```
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE,
            IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR,
            NE, SN, TD
                                          AU 1996-48973
                                                           19960111
                           19960731
    AU 9648973
                      Α1
                           19991209
    AU 713687
                      В2
    EP 802930
                           19971029
                                          EP 1996-905138
                                                           19960111
                      Α1
                      В1
                           20011219
    EP 802930
        R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE
                                          BR 1996-6735
                                                           19960111
                           19980113
    BR 9606735
                     Α
                                          CN 1996-192373
                                                           19960111
                           19980325
                     · A
    CN 1177359
                           20020925
                      В
    CN 1091449
                                          JP 1996-521815
                                                           19960111
                      T2
                          19981124
    JP 10512168
                      B2
                           20030804
    JP 3432828
                                          CA 1996-2226408 19960111
                      С
                           20011211
    CA 2226408
                      T3 20020916
                                          ES 1996-905138
                                                           19960111
    ES 2171654
                                          TW 1996-85106062 19960522
                      В
                           20011021
    TW 460302
                                          US 1996-688496 19960730
    US 5795921
                     A
                          19980818
                                                           19970709
                          19970908
                                          FI 1997-2917
    FI 9702917
                      Α
                                          NO 1997-3186
                                                           19970709
                      A
                          19970910
    NO 9703186
                                          US 1997-955555
                                                           19971020
    US 5899893
                      Α
                           19990504
                                          HK 1998-103535
                                                          19980427
                           20021025
    HK 1004140
                      A1
                                       US 1995-370697 B2 19950110
PRIORITY APPLN. INFO.:
                                       US 1995-542497 A 19951013
                                       CA 1996-2208642 A3 19960111
                                                        W 19960111
                                       WO 1996-US388
                                                      A3 19960730
                                       US 1996-688496
    Disclosed are foams capable of absorbing blood and blood-based fluids,
AΒ
     esp. menses. These absorbent foams have high capillary absorption
     pressures required of absorbents used in catamenial products, yet have
     sufficient openness to allow free movement of the insol. components in
     blood-based fluids such as menses. These absorbent foams are made by
```

polymg. high internal phase emulsions (HIPEs) where the vol. to wt. ratio of the water phase to the oil phase is in the range of from about 20:1 to about 125:1. These foams are particularly useful as absorbent members for catamenial pads. Anhyd. CaCl2 (36.32 kg) and K persulfate (567 g) were dissolved in 378 L of water to provide a water phase stream to be used in a continuous process for forming a HIPE emulsion. To a monomer combination comprising 400 g styrene, 2900 g divinylbenzene (40% divinylbenzene and 60% Et styrene), and 4800 g 2-ethylhexyl acrylate, was added 480 g of high purity diglycerol monooleate and 41 g Tinuvin 765 (antioxidant). Sep. streams of the oil phase and water phase were fed to a dynamic mixing app. The HIPE from the static mixer was collected and cured to provide a polymeric HIPE foam. The foam was sliced and the obtained sheets were subjected to compression to reduce the residual water phase content. The sheets were then resatd. with a 1% soln. of Pegosperse 200ML in water at 60.degree. and were squeezed and dried in air to obtain an absorbent foam.

dried in air to obtain an absorbent REFERENCE COUNT: 75 THERE ARE

THERE ARE 75 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
L2 ANSWER 10 OF 12 CAPLUS COPYRIGHT 2004 ACS on STN
```

ACCESSION NUMBER:

1998:705978 CAPLUS

DOCUMENT NUMBER:

129:331808

TITLE:

Recirculating a portion of high internal phase emulsions prepared in a continuous process

Desmarais, Thomas A.

PATENT ASSIGNEE(S):

The Procter & Gamble Co., USA

SOURCE:

U.S., 18 pp., Cont.-in-part of U.S. Ser. No. 370,694,

abandoned.

CODEN: USXXAM

DOCUMENT TYPE:

INVENTOR(S):

Patent English

LANGUAGE:

FAMILY ACC. NUM. COUNT: 2 PATENT INFORMATION:

ENT NO.]	KIND	DATE		APE	LICATION NO	ο.	DATE
5827909		A	19981027		US	1996-716510)	19960917
9600133		A	19960730		zA	1996-133		19960109
116709		A1	20000229		IL	1996-116709	9	19960109
2208419		AA	19960718		CA	1996-220841	19	19960111
1175911		A	19980311		CN	1996-192024	4	19960111
1050069		В	20000308					
171648		E	19981015		AT	1996-905110)	19960111
2122800		Т3	19981216		ES	1996-905110)	19960111
379233		В	20000111		TW	1996-851060	060	19960522
APPLN.	INFO.:			US	199	95-370694	B2	19950110
	5827909 9600133 116709 2208419 1175911 1050069 171648 2122800 379233 4 APPLN.	5827909 9600133 116709 2208419 1175911 1050069 171648 2122800 379233	5827909 A 9600133 A 116709 A1 2208419 AA 1175911 A 1050069 B 171648 E 2122800 T3 379233 B	5827909 A 19981027 9600133 A 19960730 116709 A1 20000229 2208419 AA 19960718 1175911 A 19980311 1050069 B 20000308 171648 E 19981015 2122800 T3 19981216 379233 B 20000111	5827909 A 19981027 9600133 A 19960730 116709 A1 20000229 2208419 AA 19960718 1175911 A 19980311 1050069 B 20000308 171648 E 19981015 2122800 T3 19981216 379233 B 20000111	5827909 A 19981027 US 9600133 A 19960730 ZA 116709 A1 20000229 IL 2208419 AA 19960718 CA 1175911 A 19980311 CN 1050069 B 20000308 171648 E 19981015 AT 2122800 T3 19981216 ES 379233 B 20000111 TW	5827909 A 19981027 US 1996-716510 9600133 A 19960730 ZA 1996-133 116709 A1 20000229 IL 1996-116709 2208419 AA 19960718 CA 1996-220841 1175911 A 19980311 CN 1996-192024 1050069 B 20000308 171648 E 19981015 AT 1996-905110 2122800 T3 19981216 ES 1996-905110 379233 B 20000111 TW 1996-851060	5827909 A 19981027 US 1996-716510 9600133 A 19960730 ZA 1996-133 116709 A1 20000229 IL 1996-116709 2208419 AA 19960718 CA 1996-2208419 1175911 A 19980311 CN 1996-192024 1050069 B 20000308 171648 E 19981015 AT 1996-905110 2122800 T3 19981216 ES 1996-905110 379233 B 20000111 TW 1996-85106060

Continuous processes for making high internal phase emulsions that are typically polymd. to provide microporous, open-celled polymeric foam materials capable of absorbing aq. fluids, esp. aq. body fluids such as urine, is improved. The improvement involves recirculating a portion (about 50% or less) of the emulsion withdrawn from the dynamic mixing zone of this continuous process. This increases the uniformity of the emulsion ultimately obtained from this continuous process in terms of having the water droplets homogeneously dispersed in the oil phase. This also improves the stability of the HIPE and expands the temp. range for pouring and curing this HIPE during subsequent emulsion polymn. The improvement also eliminates the need for a static mixer outside the dynamic mixing zone, and allows for processing where relatively low pressure drops are required across the mixing zone. A HIPE foam was prepd. by polymg. divinylbenzene, 2-ethylhexyl acrylate, and hexanediol

diacrylate in the presence of an aq. phase contg. emulsifiers. 40

REFERENCE COUNT:

THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ANSWER 11 OF 12 CAPLUS COPYRIGHT 2004 ACS on STN

1996:730408 CAPLUS ACCESSION NUMBER:

DOCUMENT NUMBER:

TITLE:

126:19720

Production of high internal phase emulsion polymerized

foams for composite processes

AUTHOR(S):

Hoisington, Mark A.; Duke, Joseph R.

CORPORATE SOURCE:

Polymers and Coatings Group, Los Alamos National

Laboratory, Los Alamos, NM, 87545, USA

SOURCE:

International SAMPE Technical Conference (1996), 28 (Technology Transfer in a Global Community),

1317-1326

CODEN: ISTCEF; ISSN: 0892-2624

PUBLISHER:

Society for the Advancement of Material and Process

Engineering

DOCUMENT TYPE: LANGUAGE:

Journal English

Heat-resistant, polymeric foams have potential applications in numerous composite structures including core material for sandwich panels and reinforcing filler of honeycomb cores. This work focused on the development of high-internal-phase (HIPE) emulsion-polymd. foams with thermal and mech. performance designed for use in composite processes. contrast to typical blown foam systems, HIPE foams were investigated in order to take advantage of their unique combination of processing and property benefits. Thermal properties of typical styrene/divinylbenzene HIPE foams were dramatically improved by copolymg. styrene with N-cyclohexylmaleimide and bismaleimide monomers in a HIPE process. This process produced polymeric, structural foams with glass transition temps. ranging from 130 - 220.degree. (265 -425.degree.F) and compression strengths of 550 - 700 kPa (80 - 100 psi) at foam densities under 80 mg/cm3 (5.0 lb/ft3).

L2 ANSWER 12 OF 12 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1996:546626 CAPLUS

DOCUMENT NUMBER: 125:257257

TITLE: Absorbent foams made from high internal phase

emulsions useful for acquiring aqueous fluids

INVENTOR(S):
Desmarais, Thomas A.

PATENT ASSIGNEE(S): The Procter and Gamble Company, USA

SOURCE: U.S., 25 pp. CODEN: USXXAM

DOCUMENT TYPE: LANGUAGE:

Patent English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE				
US 5550167 A 19960827 US 1995-520793 199508	330			
us 5571849 A 19961105 US 1996-583356 199601	19960105			
ZA 9600140 A 19960730 ZA 1996-140 199601	١09			
ZA 9600140 A 19960730 ZA 1996-140 199601 EG 22099 A 20020731 EG 1996-25 199601	10			
CA 2208575 AA 19970306 CA 1996-2208575 199601	111			
CA 2208575 C 20010327				
WO 9707832 A1 19970306 WO 1996-US433 199601	L 11			
WO 9707832 C1 20021010				
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, I	E, DK, EE,			
ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, I	LR, LS, LT,			
LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, F	₹U, SD, SE,			
SG. SI. SK. TJ. TM. TR. TT, UA, UG, UZ, VN, AZ, BY, I	KZ, RU, TJ, TM			
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, C	GB, GR, IE,			
IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, C	SN, ML, MR,			
NE SN TD				
AU 9646561 A1 19970319 AU 1996-46561 199601	111			
Δττ 728334 B2 20010104				
CN 1183728 A 19980603 CN 1996-193447 199603	111			
EP 847283 Al 19980617 EP 1996-902136 19960	111			
R: AT. BE, CH. DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, S	SE, PT, IE			
вр обо7720 д 19980707 BR 1996-7720 199601	111			
TD 11511406 P2 10001005 TP 1997-510211 19960				
NZ 301194 A 20000428 NZ 1996–301194 199603 TW 391927 B 20000601 TW 1996–85106064 199603	111			
TW 391927 B 20000601 TW 1996-85106064 199605	522			
US 5763499 A 19960609 US 1997-655765 19976	712			
FI 9702918 A 19970909 FI 1997-2918 19970°	709			
NO 9703187 A 19980428 NO 1997-3187 19970'	709			
PRIORITY APPLN. INFO.: US 1995-520793 A1 199500	B30			
WO 1996-US433 W 19960	111			
US 1996-688700 A3 19960	730			

Absorbent polymeric foam materials capable of acquiring and distributing aq. fluids, esp. discharged body fluids such as urine, are disclosed. These absorbent foams combine relatively high capillary absorption pressures and capacity-per-wt. properties that allow them to acquire fluid, with or without the aid of gravity. These absorbent foams also give up this fluid efficiently to higher absorption pressure storage materials, including foam-based absorbent fluid storage components, without collapsing. The absorbent foams are made by polymg. high internal phase emulsions (HIPEs). Collapsed HIPE foams were prepd. using CaCl2 36.32 kg and K2S2O8 189 g dissolved in 378 L H2O as an aq. phase, and a monomer combination comprising low purity divinyl benzene 1912.5 g, com. divinyl benzene 607.5 g, and 2-ethylhexyl acrylate 3480 g as an oily phase; diglycerol monooleate 360 g was added as an emulsifier.

The oil phase and aq. phase were mixed at a ratio of 4 parts water and 1 part oil to form the HIPE; HIPE was kept at 65.degree. to bring about polymn. and form the foam useful in absorbent cores of disposable diapers as well as other absorbent articles.

=> s L2 and lipase inhibitor 40949 LIPASE 9159 LIPASES 42284 LIPASE (LIPASE OR LIPASES) 430325 INHIBITOR 452093 INHIBITORS 695979 INHIBITOR (INHIBITOR OR INHIBITORS) 662 LIPASE INHIBITOR (LIPASE(W)INHIBITOR) L5 0 L2 AND LIPASE INHIBITOR => s L2 and density 232545 DENSITY 104359 DENSITIES 314214 DENSITY (DENSITY OR DENSITIES) 2 L2 AND DENSITY L6 => d L6 1-2 ibib abs hitrn ANSWER 1 OF 2 CAPLUS COPYRIGHT 2004 ACS on STN Lб ACCESSION NUMBER: 2003:325436 CAPLUS 138:310463 DOCUMENT NUMBER: Low-density materials for use in inertial TITLE: fusion targets Steckle, Warren P., Jr.; Nobile, Arthur, Jr. AUTHOR(S): Materials Science and Technology Division Polymer and CORPORATE SOURCE: Coatings Group, Los Alamos National Laboratory, Los Alamos, NM, 87545, USA Fusion Science and Technology (2003), 43(3), 301-306 SOURCE: CODEN: FSTUCY American Nuclear Society PUBLISHER: Journal; General Review DOCUMENT TYPE: English LANGUAGE: A review. Low-d. polymer foams have been an integral part of targets used in inertial confinement fusion (ICF) expts. Target designs are unique in the ICF program and targets are made on an individual basis. Costs for these targets are high due to the time required to machine, assemble and characterize each target. To produce targets in high vol. and at low cost, a polymer system is required that is amenable to scale up. High internal phase emulsion (HIPE) polystyrene is a robust system that offers great flexibility in terms of tailoring the d. and incorporating metal dopants. Emulsions used to fabricate HIPE foams currently are made in a batch process. With the use of metering pumps for both the water and oil phases, emulsions can be produced in a continuous process. This not only makes these foams potential candidates for direct-drive capsules, but high-Z dopants can be metered in making these foams attractive for hohlraum components in indirect-drive systems. Prepn. of HIPE foams are discussed for both direct-drive and indirect-drive systems.

THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

11

REFERENCE COUNT:

ACCESSION NUMBER:

1996:730408 CAPLUS

DOCUMENT NUMBER:

126:19720

TITLE:

Production of high internal phase emulsion polymerized

foams for composite processes

AUTHOR(S):

Hoisington, Mark A.; Duke, Joseph R.

CORPORATE SOURCE:

Polymers and Coatings Group, Los Alamos National

Laboratory, Los Alamos, NM, 87545, USA

SOURCE:

International SAMPE Technical Conference (1996), 28 (Technology Transfer in a Global Community),

1317-1326

CODEN: ISTCEF; ISSN: 0892-2624

PUBLISHER:

Society for the Advancement of Material and Process

Engineering

DOCUMENT TYPE:

Journal

LANGUAGE:

English

Heat-resistant, polymeric foams have potential applications in numerous composite structures including core material for sandwich panels and reinforcing filler of honeycomb cores. This work focused on the development of high-internal-phase (HIPE) emulsion-polymd. foams with thermal and mech. performance designed for use in composite processes. In contrast to typical blown foam systems, HIPE foams were investigated in order to take advantage of their unique combination of processing and property benefits. Thermal properties of typical styrene/divinylbenzene HIPE foams were dramatically improved by copolymg. styrene with N-cyclohexylmaleimide and bismaleimide monomers in a HIPE process. This process produced polymeric, structural foams with glass transition temps. ranging from 130 - 220.degree. (265 - 425.degree.F) and compression strengths of 550 - 700 kPa (80 - 100 psi) at foam densities under 80 mg/cm3 (5.0 lb/ft3).

=> lipase inhibitor and foam
LIPASE IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s lipase inhibitor and foam

40949 LIPASE

9159 LIPASES

42284 LIPASE

(LIPASE OR LIPASES)

430325 INHIBITOR

452093 INHIBITORS

695979 INHIBITOR

(INHIBITOR OR INHIBITORS)

662 LIPASE INHIBITOR

(LIPASE (W) INHIBITOR)

90153 FOAM

50588 FOAMS

99590 FOAM

(FOAM OR FOAMS)

L7

6 LIPASE INHIBITOR AND FOAM

=> d L7 1-6 ibib abs hitrn

L7 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER:

2003:875011 CAPLUS

DOCUMENT NUMBER:

139:354541

TITLE:

Personal absorbent articles containing skin

conditioners

INVENTOR(S):

Lagerstedt-Eidrup, Marie-Louise; Farbrot, Anne;

Runeman, Bo

PATENT ASSIGNEE(S):

Swed.

SOURCE:

U.S. Pat. Appl. Publ., 12 pp.

CODEN: USXXCO

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

APPLICATION NO. DATE PATENT NO. KIND DATE _____ US 2003-427980 20030502 US 2003208173 A1 20031106 US 2003-42/980 20020503 US 2002-377213P P 20020503 PRIORITY APPLN. INFO.:

The focus of the invention is an absorbent article such as a diaper, pant diaper, adult incontinence guard, sanitary napkin and the like contg. a skin conditioning agent in at least a portion of the article so as to be transferable to the skin of the wearer. The skin conditioning agent is contained in a hydrogel foam material intended to be applied in skin contact with the wearer, either directly or indirectly via a liq. permeable material. For example, a foam film contg. a polyacrylate was made first and then dispersed with a skin conditioning agent, such as aloe and vitamins to prep. the skin-contacting foam film as part of the personal absorbent articles.

ANSWER 2 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER:

2003:633280 CAPLUS

DOCUMENT NUMBER:

139:179984

TITLE:

Preparation of quinoline derivatives as neuropeptide

inhibitors

INVENTOR(S):

Mattei, Patrizio; Mueller, Werner; Neidhart, Werner;

Nettekoven, Matthias Heinrich; Pflieger, Philippe

PATENT ASSIGNEE(S):

SOURCE:

U.S. Pat. Appl. Publ., 27 pp.

CODEN: USXXCO

DOCUMENT TYPE:

Patent English

Switz.

LANGUAGE:

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATE	ENT B	NO.		KI	ND :	DATE			A.	PPLI	CATI	ои ис).	DATE			
US 2003153553 WO 2003066055		A1 20030814 A1 20030814			US 2003-358006 20030204 WO 2003-EP777 20030127												
	W:	AE,	AG,	AL,	AM,	AT,	AU,	ΑZ,	BA,	BB,	BG,	BR,	BY,	BZ,	CA,	CH,	CN,
		co,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	ES,	FI,	GB,	GD,	GE,	GH,
		GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	ΚE,	KG,	KP,	KR,	ΚZ,	LC,	LK,	LR,
		LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NO,	ΝZ,	OM,	PH,
		PL,	PT,	RO,	RU,	SD,	SE,	SG,	SK,	SL,	ТJ,	TM,	TN,	TR,	TT,	TZ,	UA,
		UG,	UZ,	VN,	YU,	ZA,	ZM,	ZW,	AM,	AZ,	BY,	KG,	ΚZ,	MD,	RU,	ТJ,	TM
	RW:													ZW,			
		CH,	CY,	CZ,	DE,	DK,	EE,	ES,	FI,	FR,	GB,	GR,	HU,	ΙE,	IT,	LU,	MC,
		NL,	PT,	SE,	SI,	SK,	TR,	BF,	ВJ,	CF,	CG,	CI,	CM,	GΑ,	GN,	GQ,	GW,
			MR,														
RITY	APP	LN.	INFO	. : ·	•	·			EP 2	002-	1967		Α	2002	0204		

PRIORITY APP

OTHER SOURCE(S): MARPAT 139:179984

GT

$$R^4$$
 R^1
 R^2
 R^3

Compds. of general formula (I) as well as pharmaceutically acceptable AΒ salts and esters thereof [R1, R2 = H, alkyl, cycloalkyl, cycloalkylalkyl, alkylcarbonyl, cycloalkylcarbonyl, cycloalkylalkylcarbonyl, aryl, aralkyl, arylcarbonyl, aralkylcarbonyl, alkoxyalkyl, hydroxyalkyl, heterocyclyl, heterocyclylalkyl, heterocyclylcarbonyl, heterocyclylalkylcarbonyl, carbocyclyl, carbocyclylalkyl, amino, alkyl-SO2-, aryl-SO2-, heterocyclyl-SO2-, SO2NH2; or R1 and R2 together with the N atom to which they are attached form a 5- to 10-membered heterocyclic ring which optionally comprises a second heteroatom selected from nitrogen or oxygen and wherein the heterocyclyc ring is optionally substituted with one or more substituents independently selected from the group consisting of alkyl and alkoxy; R3 = H, alkyl, NH2, halo; R4 = H, halogen, heterocyclyl, NH2, alkyl; A = a 5 to 7-membered satd. heterocyclic ring comprising the nitrogen atom which is attached to the quinoline ring and optionally a second heteroatom which is selected from oxygen, sulfur or nitrogen and, wherein the ring A is optionally substituted by one to three substituents independently selected from the group consisting of alkyl, alkoxy, hydroxy, amino, acetylamino, cyano, hydroxyalkyl, alkoxyalkyl, cycloalkylalkoxy, and cycloalkylalkoxyalkyl] are prepd. These compds. are potent inhibitors of neuropeptide Y and can be used in the form of pharmaceutical prepns. to reduce appetite for the treatment or prevention of various disease states and related morbidities including obesity. Thus, a suspension of 1.01 g (3 mmol) 7-iodo-2-methyl-4-pyrrolidin-1ylquinoline, 0.186 g (0.3 mmol) racemic BINAP, 33.7 mg (0.15 mmol) palladium(II) acetate, and 0.87 g (9 mmol) sodium tert-butylate in toluene (25 mL) was treated at room temp. with 0.427 g (6 mmol) aminomethylcyclopropane and then heated to reflux under an argon atm. for 20 h to give, after workup and silica gel chromatog., 253 mg (30%) cyclopropylmethyl(2- methyl-4-pyrrolidin-1-ylquinolin-7-yl)amine as light yellow foam. Isobutyl(2-methyl-4-pyrrolidin-1-ylquinolin-7yl)amine and furan-2-carboxylic acid (2-methyl-4-pyrrolidin-1-ylquinolin-7yl) amide showed IC50 of 0.7 and 0.3 nM, resp., for inhibiting the binding of [1251]peptide YY to recombinant mouse NPY5-receptor expressed in human embryonic kidney 293 cells (HEK293).

ANSWER 3 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER:

2003:376151 CAPLUS

DOCUMENT NUMBER:

PATENT ASSIGNEE(S):

138:390906

TITLE:

Use of non-digestible polymeric foams to

sequester ingested materials thereby inhibiting their

absorption by the body

INVENTOR(S):

Hird, Bryn; Jandacek, Ronald James The Procter & Gamble Company, USA

SOURCE:

U.S. Pat. Appl. Publ., 17 pp., Cont.-in-part of U.S.

Ser. No. 83,218.

CODEN: USXXCO

DOCUMENT TYPE:

Patent English

LANGUAGE:

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

```
APPLICATION NO. DATE
   PATENT NO. KIND DATE
                                   _____
    _____ ___
   US 2003091610
                                 US 2002-251376 20020920
                  A1
                      20030515
                                   US 2002-83218
                                                20020226
                  A1
                      20030417
   US 2003072804
                                 US 2001-277058P P 20010319
US 2002-83218 A2 20020226
PRIORITY APPLN. INFO.:
```

Compns. comprising an open-celled polymeric foam useful for (i) AB sequestering lipophilic materials present in the gastrointestinal tract, thereby inhibiting the absorption of such lipophilic materials by the body, (ii) sequestering aq. and/or hydrophilic materials present in the gastrointestinal tract, thereby ameliorating diarrhea, and/or (iii) ameliorating side effects assocd. with the use of lipase inhibitors are described. Polymeric foam materials is made from high internal phase emulsions (HIPE) using, e.g., diglycerol monooleate and ditallowdimethylammonium Me sulfate as the oil phase. Kits comprising (a) a first compn. contg. a non-digestible, non-absorbable, open-celled polymeric foam, and (b) a second compn. contg. a component selected from the group consisting of vitamins, lipase inhibitors, laxatives, and their combinations, and methods of using the compns. and kits are also described. For example, divinylbenzene-2-ethylhexyl acrylate-1,6-hexanediol diacrylate copolymer foam (prepn. given) was compressed into a gelatin capsule together with the lipase inhibitor Xenical.

L7 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER:

2002:736141 CAPLUS

DOCUMENT NUMBER:

137:253026

TITLE:

The use of non-digestible polymeric foams to

sequester ingested materials thereby inhibiting their

absorption by the body

INVENTOR(S):
PATENT ASSIGNEE(S):

Hird, Bryn; Jandacek, Ronald James The Procter & Gamble Company, USA

SOURCE:

PCT Int. Appl., 36 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

```
PATENT NO. KIND DATE
                                   APPLICATION NO. DATE
    ______
                                    WO 2002-US6529 20020301
   WO 2002074343 A2 20020926
WO 2002074343 A3 20030313
       W: AE, AG, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH,
          SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM,
           AZ, BY, KG, KZ
       RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
           CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
           BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
                                EP 2002-715032 20020301
                      20040102
    EP 1372673
                  A2
       R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
           IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
                                  US 2001-277058P P 20010319
PRIORITY APPLN. INFO.:
                                  WO 2002-US6529 W 20020301
```

AB Compns. comprising an open-celled polymeric **foam** useful for sequestering lipophilic materials present in the gastrointestinal tract,

thereby inhibiting the absorption of such lipophilic materials by the body are described. The compns. comprising the open-celled polymeric foam are also useful for ameliorating side effects assocd. with the use of lipase inhibitors. In a preferred embodiment, the polymeric foam materials are made from high internal phase emulsions. Also, the compns. comprising open-celled polymeric foams are useful for the purpose of sequestering aq. and/or hydrophilic materials present in the gastrointestinal tract, thereby ameliorating diarrhea. Kits comprising the compns. and methods of using the compns. and kits are also described. For example, a polymeric foam was prepd. by a high internal phase emulsion method from, e.g., 2-ethylhexyl acrylate, divinylbenzene and 1,6-hexanediol diacrylate. When 1.0% of the foam was added to rats' diet, normal fat excretion was roughly doubled; 10.99% excreted fat compared to 5.73% excreted fat in rats receiving no foam. The polymer foam was formulated into dosage forms alone or in combination with Xenical or hydroxypropyl Me cellulose.

ANSWER 5 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:10262 CAPLUS

DOCUMENT NUMBER:

136:90945

TITLE:

Preparation of stable pharmaceutical compositions

Busson, Patrick; Schroeder, Marco INVENTOR(S): F. Hoffmann-La Roche A.-G., Switz. PATENT ASSIGNEE(S):

PCT Int. Appl., 24 pp.

SOURCE:

CODEN: PIXXD2

DOCUMENT TYPE:

Patent English

LANGUAGE:

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

```
KIND DATE APPLICATION NO. DATE
    PATENT NO.
    _____
                                         _____
                                         WO 2001-EP6834 20010618
    WO 2002000201 A2 20020103
                    A3 20020418
    WO 2002000201
        W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
            CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
            GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
            LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,
            RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ,
            VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
        RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
            DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
            BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
                     A2 20030402 EP 2001-960323 20010618
    EP 1296656
            AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
                                     BR 2001-12014
                   A 20030513
                                                           20010618
    BR 2001012014
                                         US 2001-891069 20010625
                      A1 20020214
    US 2002018812
                     B2 20030318
    US 6534087
                                       US 2002-266363 20021008
NO 2002-6197 20021223
    US 2003039614 A1 20030227
NO 2002006197 A 20021223
                                       EP 2000-113535 A 20000627
PRIORITY APPLN. INFO.:
                                       WO 2001-EP6834 W 20010618
US 2001-891069 A1 20010625
```

The present invention relates to a method for the prepn. of pharmaceutical AΒ compns., in the form of expanded, mech. stable, lamellar, porous, sponge-like or foam structures out of solns. and dispersions. This method comprises the steps of prepg. a soln. or a homogeneous dispersion of a liq. and a compd. selected from the group consisting of 1 or more drugs, 1 or more excipients, and mixts., followed by the expansion of the soln. or the homogeneous dispersion without boiling. The invention also relates to the compns., their further processing and any corresponding dosage forms obtainable by the above method. Thus, a compn. contained oseltamivir 10.0, polymethacrylate 90.0, and isopropanol 80.0%.

L7 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER:

1999:492764 CAPLUS

DOCUMENT NUMBER:

131:335379

TITLE:

Modification of type III VLDL, their remnants, and

VLDL from APOE-knockout mice by phydroxyphenylacetaldehyde, a product of

myeloperoxidase activity, causes marked cholesteryl

ester accumulation in macrophages

AUTHOR(S):

Whitman, Stewart C.; Hazen, Stanley L.; Miller, David B.; Hegele, Robert A.; Heinecke, Jay W.; Huff, Murray

W.

CORPORATE SOURCE:

Departments of Biochemistry and Medicine and the Robarts Research Institute, University of Western

Ontario, London, ON, N6A 5K8, Can.

SOURCE:

Arteriosclerosis, Thrombosis, and Vascular Biology

(1999), 19(5), 1238-1249

CODEN: ATVBFA; ISSN: 1079-5642 Lippincott Williams & Wilkins

PUBLISHER: DOCUMENT TYPE:

Journal English

89

DOCUMENT TY

LANGUAGE: Very-low-d. lipoproteins (VLDLs) from apolipoprotein (apo) E2/E2 subjects with type III hyperlipoproteinemia, their VLDL remnants, and VLDL from apoE-knockout (EKO) mice are taken up poorly by macrophages. The present study examd. whether VLDL modification by the reactive aldehyde p-hydroxyphenylacetaldehyde (pHA) enhances cholesteryl ester (CE) accumulation by J774A.1 macrophages. PHA is the major product derived from the oxidn. of L-tyrosine by myeloperoxidase and is a component of human atherosclerotic lesions. Incubation of J774A.1 cells with native type III VLDL, their remnants, and EKO-VLDL increased cellular CE by only 3-, 5-, and 5-fold, resp., compared with controls. In striking contrast, cells exposed to VLDL modified by purified pHA (pHA-VLDL) exhibited marked increases in cellular CE of 38-, 47-, and 35-fold, resp. Addn. of the lipoprotein lipase inhibitor tetrahydrolipstatin decreased cellular CE accumulation induced by the 3 pHA-modified VLDL prepns. by 73%, 59%, and 73%, resp. Addn. of the acyl CoA:cholesterol acyltransferase inhibitor DuP 128 to cells incubated with the pHA-modified lipoproteins decreased cellular CE by 100%, 82%, and 95%, resp., but had no effect on cellular triglycerides. To examine whether the type A scavenger receptors (SR-As) mediated the uptake of pHA-VLDL, incubations were performed in the presence of polyinosine (poly I), a polynucleotide known to block binding to SR-As (types I and II), or in cells preincubated with interferon-.gamma. (IFN-.gamma.), a cytokine known to decrease expression of SR-A type I. Coincubation of pHA-VLDL with poly I reduced cellular CE by only 38%, 44%, and 49%, resp., whereas coincubation with IFN-.gamma. reduced CE by only 18%, 27%, and 65%, resp. In marked contrast to pHA-VLDL, both poly I and IFN-.gamma. inhibited, by>95%, CE accumulation induced by copper-oxidized VLDL. These results demonstrate a novel mechanism for the conversion of type III VLDLs, their remnants, and EKO-VLDL into atherogenic particles and suggest that macrophage uptake of pHA-VLDL (1) requires catalytically active lipoprotein lipase, (2) involves acyl CoA: cholesterol acyltransferase-mediated cholesterol esterification, and (3) involves pathways distinct from the SR-A.

REFERENCE COUNT:

THERE ARE 89 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

14320 OPENS 224494 OPEN

(OPEN OR OPENS)

1554 CELLED

611 OPEN CELLED

(OPEN (W) CELLED)

L8 2 L7 AND OPEN CELLED

=> d L8 1-2 ibib abs hitrn

L8 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER:

2003:376151 CAPLUS

DOCUMENT NUMBER:

138:390906

TITLE:

Use of non-digestible polymeric foams to

sequester ingested materials thereby inhibiting their

absorption by the body

INVENTOR(S):
PATENT ASSIGNEE(S):

Hird, Bryn; Jandacek, Ronald James The Procter & Gamble Company, USA

SOURCE:

U.S. Pat. Appl. Publ., 17 pp., Cont.-in-part of U.S.

Ser. No. 83,218.

CODEN: USXXCO

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
US 2003091610	A1	20030515	00 2002 2020	20020920	
US 2003072804	Al	20030417	00 2002 00210		
PRIORITY APPLN. INFO.	:		US 2001-277058P P	20010319	
			US 2002-83218 A2	20020226	

Compns. comprising an open-celled polymeric AΒ foam useful for (i) sequestering lipophilic materials present in the gastrointestinal tract, thereby inhibiting the absorption of such lipophilic materials by the body, (ii) sequestering aq. and/or hydrophilic materials present in the gastrointestinal tract, thereby ameliorating diarrhea, and/or (iii) ameliorating side effects assocd. with the use of lipase inhibitors are described. Polymeric foam materials is made from high internal phase emulsions (HIPE) using, e.g., diglycerol monooleate and ditallowdimethylammonium Me sulfate as the oil phase. Kits comprising (a) a first compn. contg. a non-digestible, non-absorbable, open-celled polymeric foam, and (b) a second compn. contg. a component selected from the group consisting of vitamins, lipase inhibitors, laxatives, and their combinations, and methods of using the compns. and kits are also described. For example, divinylbenzene-2-ethylhexyl acrylate-1,6hexanediol diacrylate copolymer foam (prepn. given) was compressed into a gelatin capsule together with the lipase inhibitor Xenical.

L8 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER:

2002:736141 CAPLUS

DOCUMENT NUMBER:

137:253026

TITLE:

The use of non-digestible polymeric foams to

sequester ingested materials thereby inhibiting their

absorption by the body

INVENTOR(S):

Hird, Bryn; Jandacek, Ronald James The Procter & Gamble Company, USA

PATENT ASSIGNEE(S): SOURCE:

PCT Int. Appl., 36 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE WO 2002074343 A2 20020926 WO 2002-US6529 20020301 WO 2002074343 A3 20030313 W: AE, AG, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG EP 1372673 A2 20040102 EP 2002-715032 20020301 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR US 2001-277058P P 20010319 PRIORITY APPLN. INFO.: WO 2002-US6529 W 20020301

Compns. comprising an open-celled polymeric AΒ foam useful for sequestering lipophilic materials present in the gastrointestinal tract, thereby inhibiting the absorption of such lipophilic materials by the body are described. The compns. comprising the open-celled polymeric foam are also useful for ameliorating side effects assocd. with the use of lipase inhibitors. In a preferred embodiment, the polymeric foam materials are made from high internal phase emulsions. Also, the compns. comprising open-celled polymeric foams are useful for the purpose of sequestering aq. and/or hydrophilic materials present in the gastrointestinal tract, thereby ameliorating diarrhea. Kits comprising the compns. and methods of using the compns. and kits are also described. For example, a polymeric foam was prepd. by a high internal phase emulsion method from, e.g., 2-ethylhexyl acrylate, divinylbenzene and 1,6-hexanediol diacrylate. When 1.0% of the foam was added to rats' diet, normal fat excretion was roughly doubled; 10.99% excreted fat compared to 5.73% excreted fat in rats receiving no foam. The polymer foam was formulated into dosage forms alone or in combination with Xenical or hydroxypropyl Me cellulose.